Peer-reviewed veterinary case report
Serum biomarker tests for diagnosing and monitoring canine lymphoma
By Bryan, Jeffrey N·Published in Frontiers in veterinary science·2016·Department of Veterinary Medicine and Surgery, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The Current State of Clinical Application of Serum Biomarkers for Canine Lymphoma.
- Species:
- dog
Plain-English summary
A dog with lymphoma may show symptoms like weight loss, lethargy, or swollen lymph nodes. Veterinarians have been using blood tests that measure specific proteins and enzymes, such as C-reactive protein and thymidine kinase 1, to help diagnose and monitor the disease. These tests can indicate how active the lymphoma is and whether the dog is responding to treatment. While these biomarkers can be helpful, more research is needed to see if acting on these results early can improve the dog's overall health and lifespan.
People also search for: dog lymphoma symptoms · canine cancer blood test · lymphoma treatment for dogs
Abstract
Serum biomarkers of canine lymphoma activity for diagnosis, prognosis, and therapy monitoring have been of clinical interest for more than a decade. Tumor products, biochemical enzymes, cytokines, metabolic profiling, leakage enzymes, as well as serum proteins have been studied as biomarkers for lymphoma. Multiple biomarkers combined have been shown to be most sensitive and specific. C-reactive protein, thymidine kinase 1, and haptoglobin have been most extensively studied and commercialized in diagnostic tests, the TK Canine Cancer Panel and the Canine Lymphoma Blood Test. These tests have been evaluated either in cohorts of diseased and healthy dogs or in prospective studies of ill dogs, respectively, for application to clinical decision-making. Some evidence exists for application of these tests, but large-scale studies are lacking in a broad range of lymphoma forms. These biomarkers are commonly elevated at diagnosis and at relapse. Further study is necessary to determine if early intervention guided by biomarker elevation will improve quantity or quality of life for dogs with lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27747218/